ALZpath and Quanterix Expand Alzheimer's Biomarker Research Agreement
ALZpath, Inc. and Quanterix have expanded their strategic licensing agreement to advance next-generation Alzheimer's disease biomarker research. Specific details regarding the expansion have not been disclosed.
ALZpath, Inc. and Quanterix have broadened their strategic licensing agreement, aiming to accelerate the development of next-generation biomarkers for Alzheimer's disease. The companies have not provided specific details regarding the scope or terms of the expansion.
This expanded collaboration is expected to enhance research capabilities in identifying and validating critical biomarkers for Alzheimer's, potentially leading to earlier and more accurate diagnoses. The partnership leverages ALZpath's expertise in Alzheimer's diagnostics and Quanterix's high-sensitivity protein detection technology.
ALZpath focuses on developing diagnostic tools for Alzheimer's, enabling the measurement of disease-related proteins in blood samples. Quanterix provides platforms for ultrasensitive biomarker quantification, crucial for detecting subtle biological changes.
The agreement aims to support the broader scientific community in their pursuit of understanding and combating Alzheimer's disease. Further information on the technical aspects of the expanded license and its anticipated impact on research timelines is expected to be released in the future.